We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Press & Announcements

Organogenesis’ Advanced Wound Care Portfolio Highlighted at SAWC Fall 2016

CANTON, Mass. and LAS VEGAS, Nev. ‐ Oct. 6, 2016 – This week, new data and information featuring Organogenesis’ FDA-approved bioengineered cell-based products Apligraf® and Dermagraft®, and wound management products PuraPly™ and PuraPly Antimicrobial (AM)™ will be presented at the Fall Symposium on Advanced Wound Care (SAWC), the nation’s largest interdisciplinary wound care forum, held October 7-9, 2016 in Las Vegas.

"As the nation’s leading developer of advanced wound care innovations and technologies, we look forward to demonstrating how clinicians are utilizing our versatile product portfolio to treat wounds across all phases of healing,” said Gary S. Gillheeney, Sr., President and CEO of Organogenesis.

Clinical presentations include award-winning research from a multidisciplinary team at the University of Miami that provides insight on what happens to a patient's genomic profile when Apligraf is applied to a chronic venous leg ulcer (VLU), when compared to conventional therapy alone. The analysis found that Apligraf altered specific molecular and cellular responses in the wound environment, reversing the chronic wound profile to resemble more of an acute wound profile.

Other presentations include several new case series evaluating PuraPly and PuraPly Antimicrobial in the management of several types of wounds.

Additionally, product information will be available at the Organogenesis booth (#301) in the conference exhibit hall.


Evaluation of a Purified Collagen Matrix with PHMB on the Proliferation of Methicillin Resistant Staphylococcus aureus (MRSA) in a Porcine Wound Model
M. Solis, J. Gil, J. Valdes, A. Higa and S.C. Davis
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL

PHMB Incorporated into an Acellular Matrix as a Product Effective in The Treatment of Wounds
C.G. Marchese
D.P.M, F.A.C.F.A.S, F.A.P.W.H

The Use of a New Purified Collagen Matrix to Support Healing in Recalcitrant Wounds
M. Gehling, J. Samies
The Regional Medical Wound Center, Orangeburg, SC

A Case Series Using a New Purified Collagen Matrix with PHMB on Recalcitrant Wounds of Various Etiologies
D. Lintzeris, K. Vernon, H. Percise, A. Strickland, K. Yarrow, A. White, M. Gurganus, S. Sherrod, K. Vergin and L. Johnson
Wayne Memorial Wound Healing and Hyperbaric Center, Goldboro, NC

About Organogenesis

Massachusetts-based Organogenesis Inc. is a global leader in advanced wound care innovation and technologies, including bio-active wound healing and soft tissue regeneration. Organogenesis’ versatile portfolio of advanced wound care products is designed to treat a variety of wounds and support clinicians across all phases of the wound healing process. The company’s product portfolio includes FDA-approved Apligraf® and Dermagraft®, the best-in-class products for bio-active wound healing, and the recently launched, FDA-cleared PuraPly Antimicrobial™, which manages bioburden and supports healing for a wide variety of wound types.

« Back to Press Releases and Announcements